Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia: Comparison with antigen receptor-based MRD quantification methods

Leukemia Research

Volumn 28, Issue 7, 2004, Pages 699-706

  Taube, Tillmann ^a   Eckert, Cornelia ^a   Körner, Gabriele ^a   Henze, Günter ^a   Seeger, Karlheinz ^a  

^a Klin F Padiatrie Mit S   (Germany)

Author keywords

Acute lymphoblastic leukaemia; LightCycler; Minimal residual disease; Quantitative real time PCR; TEL AML1

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DNA DETERMINATION; GENE FUSION; HUMAN; MEDICAL ASSESSMENT; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

BONE MARROW; CHILD; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FLUORESCENCE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN; RECURRENCE; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 2442552936     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.11.006     Document Type: Article

References (25)

1. Golub T.R., Barker G.F., Bohlander S.K., Hiebert S.W., Ward D.C., Bray Ward P., et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U.S.A. 92:1995;4917-4921
2. Nakao M., Yokota S., Horiike S., Taniwaki M., Kashima K., Sonoda Y., et al. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia. 10:1996;1463-1470
3. Shurtleff S.A., Buijs A., Behm F.G., Rubnitz J.E., Raimondi S.C., Hancock M.L., et al. TEL/AML1 fusion resulting from a cryptic t(1221) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 9:1995;1985-1989
4. Borkhardt A., Cazzaniga G., Viehmann S., Valsecchi M.G., Ludwig W.D., Burci L., et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood. 90:1997;571-577
5. Seeger K., Adams H.P., Buchwald D., Beyermann B., Kremens B., Niemeyer C., et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood. 91:1998;1716-1722
6. van Dongen J.J., Seriu T., Panzer Grumayer E.R., Biondi A., Pongers Willemse M.J., Corral L., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 352:1998;1731-1738
7. Cave H., van der Werff ten Bosch J., Suciu S., Guidal C., Waterkeyn C., Otten J., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group [see comments]. N. Engl. J. Med. 339:1998;591-598
8. Coustan-Smith E., Sancho J., Hancock M.L., Boyett J.M., Behm F.G., Raimondi S.C., et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 96:2000;2691-2696
9. Eckert C., Biondi A., Seeger K., Cazzaniga G., Hartmann R., Beyermann B., et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 358:2001;1239-1241
10. Pongers Willemse M.J., Verhagen O.J., Tibbe G.J., Wijkhuijs A.J., de Haas V., Roovers E., et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia. 12:1998;2006-2014
11. Eckert C., Landt O., Taube T., Seeger K., Beyermann B., Proba J., et al. Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 14:2000;316-323
12. de Haas V., Breunis W.B., Verhagen O.J., van der Berg H., van der Schoot C.E. Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reavtion identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse [letter]. Blood. 96:2000;1619-1620
13. van Dongen J.J., Szczepanski T., de Bruijn M.A., van den Beemd M.W., de Bruin Versteeg S., Wijkhuijs J.M., et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol. Ther. 2:1996;121-133
14. van Dongen J.J., Breit T.M., Adriaansen H.J., Beishuizen A., Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia. 6(Suppl 1):1992;47-59
15. Szczepanski T., Beishuizen A., Pongers Willemse M.J., Hahlen K., Van Wering E.R., Wijkhuijs A.J., et al. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. Leukemia. 13:1999;196-205
16. Satake N., Kobayashi H., Tsunematsu Y., Kawasaki H., Horikoshi Y., Koizumi S., et al. Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21). Br. J. Haematol. 97:1997;607-611
17. Pallisgaard N., Clausen N., Schroder H., Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(1221) TEL-AML1 fusion transcript. Genes Chromosomes Cancer. 26:1999;355-365
18. Ballerini P., Landman Parker J., Laurendeau I., Olivi M., Vidaud M., Adam M., et al. Quantitative analysis of TEL/AML1 fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia [letter]. Leukemia. 14:2000;1526-1528
19. Fasching K., Konig M., Hettinger K., Mann G., Gadner H., Haas O.A., et al. MRD levels during the first months of treatment indicate relapses in children with t(1221)-positive ALL [letter]. Leukemia. 14:2000;1707-1708
20. Cayuela J.M., Baruchel A., Orange C., Madani A., Auclerc M.F., Daniel M.T., et al. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood. 88:1996;302-308
21. Park H.J., Lee K.E., Um J.M., Choe S.Y., Chi X.Z., Lee J.A., et al. Molecular detection of TEL-AML1 transcripts as a diagnostic tool and for monitoring of minimal residual disease in B-lineage childhood acute lymphoblastic leukemia. Mol. Cells. 10:2000;90-95
22. Drunat S., Olivi M., Brunie G., Grandchamp B., Vilmer E., Bieche I., et al. Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 114:2001;281-289
23. de Haas V., Breunis W.B., Dee R., Verhagen O.J., Kroes W., van Wering E.R., et al. The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia. Br. J. Haematol. 116:2002;87-93
24. van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 13:1999;1901-1928
25. Brumpt C., Delabesse E., Beldjord K., Davi F., Cayuela J.M., Millien C., et al. The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. Blood. 96:2000;2254-2261